MLH1 deficiency suppresses glioblastoma growth and enhances αPD-1 efficacy via the cGAS/STING pathway

Glioblastoma (GBM) resistance to immune checkpoint inhibitors remains a major clinical challenge, largely due to its immunosuppressive tumor microenvironment. DNA mismatch repair protein MutL Homolog 1 (MLH1) participates in genome stability maintenance, yet its functional role and regulatory mechanism modulating GBM anti-tumor immunity remain poorly defined. Here we show MLH1 is overexpressed in GBM and correlates with immune regulation. Mechanistically, MLH1 associates with EXO1 and negatively regulates its protein expression. MLH1 knockdown relieves this suppression, which is accompanied by EXO1 accumulation, DNA damage, cGAS/STING pathway activation, and increased IFN- β production, all of which are reversed by the co-knockdown of MLH1 and EXO1. In orthotopic and subcutaneous syngeneic glioma models, MLH1 knockdown suppressed tumor growth and was accompanied by increased CD8 + cell infiltration and elevated expression of effector molecules. Furthermore, combining MLH1 knockdown with αPD-1 therapy exerted enhanced anti-tumor efficacy. Collectively, MLH1 deficiency activates the cGAS/STING pathway in association with EXO1, and enhances the efficacy of PD-1 blockade, which may provide a potential therapeutic strategy to overcome immunotherapy resistance in GBM.

Authors

Institutions

Publication Details

Journal
Cancer Immunology Immunotherapy
Published
2026-11-21
DOI
https://doi.org/10.1007/s00262-026-04651-1
Primary Topic
Cancer Immunotherapy and Biomarkers
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

MLH1 deficiency suppresses glioblastoma growth and enhances αPD-1 efficacy via the cGAS/STING pathway

周静铮, Shuxin Song, Bing Xiao, Jianming Zhu et al.
Cancer Immunology Immunotherapy
Cancer Immunotherapy and Biomarkers
article

MLH1 deficiency suppresses glioblastoma growth and enhances αPD-1 efficacy via the cGAS/STING pathway

周静铮, Shuxin Song, Bing Xiao, Jianming Zhu, Wei He, Zhihua Chen, Hongbing Wu
article en

Abstract

Glioblastoma (GBM) resistance to immune checkpoint inhibitors remains a major clinical challenge, largely due to its immunosuppressive tumor microenvironment. DNA mismatch repair protein MutL Homolog 1 (MLH1) participates in genome stability maintenance, yet its functional role and regulatory mechanism modulating GBM anti-tumor immunity remain poorly defined. Here we show MLH1 is overexpressed in GBM and correlates with immune regulation. Mechanistically, MLH1 associates with EXO1 and negatively regulates its protein expression. MLH1 knockdown relieves this suppression, which is accompanied by EXO1 accumulation, DNA damage, cGAS/STING pathway activation, and increased IFN- β production, all of which are reversed by the co-knockdown of MLH1 and EXO1. In orthotopic and subcutaneous syngeneic glioma models, MLH1 knockdown suppressed tumor growth and was accompanied by increased CD8 + cell infiltration and elevated expression of effector molecules. Furthermore, combining MLH1 knockdown with αPD-1 therapy exerted enhanced anti-tumor efficacy. Collectively, MLH1 deficiency activates the cGAS/STING pathway in association with EXO1, and enhances the efficacy of PD-1 blockade, which may provide a potential therapeutic strategy to overcome immunotherapy resistance in GBM.

Cancer Immunology Immunotherapy
Second Affiliated Hospital of Nanchang University (CN)
Cancer Immunotherapy and Biomarkers
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon